Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. Case presentation We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external beam...

Full description

Bibliographic Details
Main Authors:	Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya
Format:	Article
Language:	English
Published:	Wiley 2022-07-01
Series:	IJU Case Reports
Subjects:	castration‐resistant prostate cancer (CRPC) with neuroendocrine differentiation prostate cancer salvage focal brachytherapy
Online Access:	https://doi.org/10.1002/iju5.12442

Similar Items

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
by: Soichiro Yoshida, et al.
Published: (2021-07-01)

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control
by: Esther Mayrata, et al.
Published: (2021-02-01)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
by: Ken Kamisawa, et al.
Published: (2019-07-01)

First experience of salvage HDR brachytherapy after prostate cancer radiotherapy
by: Juras Kišonas, et al.
Published: (2015-03-01)

Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of 125I brachytherapy and robot-assisted radical prostatectomy
by: Shinya Sutani, et al.
Published: (2019-06-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases
by: Makito Miyake, et al.
Published: (2017-07-01)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
by: Huub H. van Rossum, et al.
Published: (2023-02-01)

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan
by: Wei-Chun Weng, et al.
Published: (2022-10-01)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01)

The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
by: Wojciech M. Burchardt, et al.
Published: (2023-04-01)

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01)

Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
by: Metha Maenhout, et al.
Published: (2017-04-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity
by: Thirza Opbroek, et al.
Published: (2023-03-01)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
by: Tomohiro Iwasawa, et al.
Published: (2022-06-01)

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer
by: Jun A, et al.
Published: (2021-02-01)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
by: Yota Yasumizu, et al.
Published: (2021-03-01)

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
by: Diana V. Maslov, et al.
Published: (2023-03-01)

Polygodial, a Sesquiterpene Dialdehyde, Activates Apoptotic Signaling in Castration-Resistant Prostate Cancer Cell Lines by Inducing Oxidative Stress
by: Reshmii Venkatesan, et al.
Published: (2022-10-01)

Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer
by: Shuichi Nishimura, et al.
Published: (2018-05-01)

Zhoushi Qi Ling decoction inhibits the progression of castration-resistant prostate cancer in vivo by regulating macrophage infiltration via IL6-STAT3 signaling
by: Hongwen Cao, et al.
Published: (2024-01-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Comparative cost-effectiveness of focal and total salvage 125 I brachytherapy for recurrent prostate cancer after primary radiotherapy
by: Max Peters, et al.
Published: (2016-12-01)

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
by: Cynthia Ménard, et al.
Published: (2022-08-01)

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
by: Cynthia Ménard, et al.
Published: (2022-11-01)

Robotic Salvage Seminal Vesiculectomy for radio-recurrent prostate cancer post LDR brachytherapy following multiple negative trans-perineal biopsies
by: Dr Athos Katelaris, et al.
Published: (2022-07-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer
by: Manabu Kato, et al.
Published: (2023-11-01)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
by: Yan Li, et al.
Published: (2022-10-01)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
by: Yozo Mitsui, et al.
Published: (2023-06-01)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
by: Daisuke Obinata, et al.
Published: (2023-04-01)

Metronomic Chemotherapy in Prostate Cancer
by: Piotr J. Wysocki, et al.
Published: (2022-05-01)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
by: Marco Bergamini, et al.
Published: (2022-07-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
by: Turco F, et al.
Published: (2022-09-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis
by: Hui Fang, et al.
Published: (2021-06-01)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01)